EXTON, PA — West Pharmaceutical Services Inc. (NYSE: WST) reported first-quarter 2026 net sales of $844.9 million and diluted earnings per share of $1.92, reflecting increases of 21.0% and 56.1%, respectively, from the prior-year period.
Adjusted diluted earnings per share rose 46.9% to $2.13.
Operating cash flow totaled $89.9 million, with capital expenditures of $42.7 million, resulting in free cash flow of $47.2 million.
The company repurchased 1.2 million shares during the quarter for $297.6 million at an average price of $243.57 per share.
Net sales in the proprietary products segment increased 23.3% to $694.3 million, driven by growth in high-value product components and delivery devices.
High-value product components generated $409.3 million in net sales, up 29.6%, while delivery devices rose 29.0% to $123.6 million.
Standard products net sales increased 6.7% to $161.4 million.
The West Vantage segment, formerly contract-manufactured products, reported net sales of $150.6 million, up 11.6%.
West increased its full-year 2026 net sales guidance to a range of $3.295 billion to $3.350 billion and raised its adjusted diluted earnings per share guidance to a range of $8.40 to $8.75.
For the second quarter, the company expects net sales between $830 million and $850 million and adjusted diluted earnings per share between $2.05 and $2.12.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.